CY1113319T1 - Συνδυασμος αερολυματοποιημενης φως φομυκινης/τομπραμυκινης για την αγωγη τησκυστικης ινωσης - Google Patents

Συνδυασμος αερολυματοποιημενης φως φομυκινης/τομπραμυκινης για την αγωγη τησκυστικης ινωσης

Info

Publication number
CY1113319T1
CY1113319T1 CY20121101067T CY121101067T CY1113319T1 CY 1113319 T1 CY1113319 T1 CY 1113319T1 CY 20121101067 T CY20121101067 T CY 20121101067T CY 121101067 T CY121101067 T CY 121101067T CY 1113319 T1 CY1113319 T1 CY 1113319T1
Authority
CY
Cyprus
Prior art keywords
combination
phosphomycin
tobramycin
tombramykin
fomykin
Prior art date
Application number
CY20121101067T
Other languages
English (en)
Inventor
William Baker
David Macleod
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of CY1113319T1 publication Critical patent/CY1113319T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D85/00—Containers, packaging elements or packages, specially adapted for particular articles or materials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/107497—Preparation composition [e.g., lysing or precipitation, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Mechanical Engineering (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Περιγράφεται μια φαρμακοτεχνική μορφή συνδυασμού φωσφομυκίνης και τομπραμυκίνης για απελευθέρωση μέσω αερολυματοποίησης. Η συμπυκνωμένη φαρμακοτεχνική μορφή συνδυασμού φωσφομυκίνης τομπραμυκίνης περιέχουσα μία αποτελεσματική ποσότητα φωσφομυκίνης και τομπραμυκίνης είναι σε θέση να αναστείλει τα ευεπηρέαστα βακτηρίδια. Η φωσφομυκίνη και η τομπραμυκίνη τυποποιούνται παρασκευαστικώς ξεχωριστά μέσα σε μία διπλή φύσιγγα έτσι ώστε όταν ανασυσταίνονται, το pΗ να είναι μεταξύ 4.5 και 8.0 ή ως μία ξηρά κόνις. Η μέθοδος για αγωγή των λοιμώξεων της αναπνευστικής οδού μέσω μιας φαρμακοτεχνικής μορφής που απελευθερώνεται ως ένα αερόλυμα έχον μέση κατά μέσο όρο διάμετρο μάζας που είναι επικρατέστερα μεταξύ 1 έως 5 [mμ], παράγεται μέσω ενός νεφελοποιητή αεριώθησης ή υπερηχητικό νεφελοποιητή (ή ισοδύναμο) ή εισπνευστήρα ξηρών κόνεων.
CY20121101067T 2004-05-17 2012-11-09 Συνδυασμος αερολυματοποιημενης φως φομυκινης/τομπραμυκινης για την αγωγη τησκυστικης ινωσης CY1113319T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57173904P 2004-05-17 2004-05-17
US65900505P 2005-03-03 2005-03-03
EP10168285A EP2266534B1 (en) 2004-05-17 2005-05-02 Aerosolized Fosfomycin/Tobramycin combination for the treatment of Cystic Fibrosis

Publications (1)

Publication Number Publication Date
CY1113319T1 true CY1113319T1 (el) 2016-04-13

Family

ID=35394588

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20111100268T CY1112004T1 (el) 2004-05-17 2011-03-09 Αερολυματοποιημενος συνδυασμος φωσφομυκινης/αμινογλυκοζιτη για την αγωγη των βακτηριδιακων αναπνευστικων λοιμωξεων
CY20121100798T CY1113283T1 (el) 2004-05-17 2012-09-05 Αερολυματοποιημενος συνδυασμος φωσφομυκινης/τομπραμυκινης για την αγωγη των βακτηριδιακων αναπνευστικων λοιμωξεων
CY20121101067T CY1113319T1 (el) 2004-05-17 2012-11-09 Συνδυασμος αερολυματοποιημενης φως φομυκινης/τομπραμυκινης για την αγωγη τησκυστικης ινωσης

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY20111100268T CY1112004T1 (el) 2004-05-17 2011-03-09 Αερολυματοποιημενος συνδυασμος φωσφομυκινης/αμινογλυκοζιτη για την αγωγη των βακτηριδιακων αναπνευστικων λοιμωξεων
CY20121100798T CY1113283T1 (el) 2004-05-17 2012-09-05 Αερολυματοποιημενος συνδυασμος φωσφομυκινης/τομπραμυκινης για την αγωγη των βακτηριδιακων αναπνευστικων λοιμωξεων

Country Status (19)

Country Link
US (4) US7943118B2 (el)
EP (3) EP1750667B1 (el)
JP (1) JP4745340B2 (el)
AR (1) AR048793A1 (el)
AT (1) ATE493969T1 (el)
AU (2) AU2005244153B2 (el)
BR (1) BRPI0509026A (el)
CA (1) CA2564546C (el)
CY (3) CY1112004T1 (el)
DE (1) DE602005025754D1 (el)
DK (3) DK2266534T3 (el)
ES (3) ES2358024T3 (el)
HK (2) HK1151191A1 (el)
IL (2) IL179277A (el)
PL (3) PL2316419T3 (el)
PT (3) PT2266534E (el)
SI (3) SI2266534T1 (el)
TW (1) TWI409074B (el)
WO (1) WO2005110022A2 (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2316419T3 (pl) 2004-05-17 2012-12-31 Gilead Sciences Inc Aerolizowana kombinacja fosfomycyna/tobramycyna do leczenia bakteryjnych infekcji dróg oddechowych
US20060210483A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
ES2666276T3 (es) 2006-10-11 2018-05-03 Laboratoires Smb Sa Composición farmacéutica antiinfecciosa para inhalación
US20100063005A1 (en) * 2006-12-11 2010-03-11 Kaare Fiala Methods for Treating Cystic Fibrosis or Pneumonia with Bacterial Infection via Pulmonary Administration of Fosfomycin
EP2018864A1 (en) 2007-07-23 2009-01-28 Biomet Deutschland GmbH Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition
DE102008046610A1 (de) * 2008-09-09 2010-03-11 Biomet Deutschland Gmbh Verwendung einer pharmazeutischen Zusammensetzung zur lokalen Infektionstherapie sowie Medizinprodukt
EP2349278A1 (en) * 2008-10-21 2011-08-03 Gilead Sciences, Inc. Fosfomycin/tobramycin combinations for the treatment and prevention of ophthalmic, otological and dermatological infections
JP2013512193A (ja) * 2009-11-24 2013-04-11 ギリアード サイエンシーズ， インコーポレイテッド 慢性閉塞性肺疾患の処置のための吸入型ホスホマイシン／トブラマイシン
US8642039B2 (en) * 2009-12-22 2014-02-04 Kalobios Pharmaceuticals, Inc. Method of treating a staphylococcus infection in a patient having a low-level pathogenic Pseudomonas aeruginosa infection
US20130164351A1 (en) * 2010-08-30 2013-06-27 Cempra Pharmaceuticals Inc. Methods of treating bacterial infections through pulmonary delivery of fusidic acid
WO2012154483A1 (en) 2011-05-06 2012-11-15 Gilead Sciences, Inc. Dry powder fosfomycin/tobramycin formulation for inhalation
US9572774B2 (en) 2011-05-19 2017-02-21 Savara Inc. Dry powder vancomycin compositions and associated methods
US8826904B2 (en) 2011-07-12 2014-09-09 Cardeas Pharma Corporation Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis
BR112014000275A2 (pt) * 2011-07-12 2017-04-18 Cardeas Pharma Inc formulações aperfeiçoadas de combinações de aminoglicosídeo e fosfomicina e métodos e sistemas para o tratamento de pneumonia associada à ventilação mecânica (pavm) e traqueobronquite associada à ventilação mecânica (vat)
PT2567691E (pt) 2011-09-12 2015-04-09 Pari Pharma Gmbh Composições aquosas que compreendem arbecacina
CA2922337A1 (en) 2013-08-26 2015-03-05 Cardeas Pharma Corporation Formulations of aminoglycosides and fosfomycin in a combination having improved chemical properties
EP3219305A1 (de) * 2016-03-16 2017-09-20 Apostolos Georgopoulos Fosfomycin-formulierung zur parenteralen verabreichung

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5750919A (en) 1980-09-16 1982-03-25 Meiji Seika Kaisha Ltd Agent for reducing side effect
JPS58134028A (ja) 1982-02-05 1983-08-10 Meiji Seika Kaisha Ltd アミノ配糖体抗生物質腎毒性の軽減乃至予防剤
GB9103291D0 (en) * 1991-02-15 1991-04-03 Waverley Pharma Ltd Transfer adaptor
US5488038A (en) 1992-11-27 1996-01-30 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Dibekacin derivatives and arbekacin derivatives active against resistant bacteria
US5508269A (en) 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
JPH09183730A (ja) 1995-05-10 1997-07-15 Meiji Seika Kaisha Ltd ホスホマイシン鏡像異性体を含んでなる医薬
US6083922A (en) 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
WO1999017782A1 (fr) 1997-10-03 1999-04-15 Meiji Seika Kaisha Ltd. Composition pour le traitement du diabete et procede de traitement du diabete
EP1161247A4 (en) 1998-12-17 2002-05-15 Chiron Corp Treatment method for severe chronic bronchitis (bronchiectasis) using an antibiotic aerosol
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
NZ523693A (en) 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
JP2005511477A (ja) * 2001-03-19 2005-04-28 プラエシス ファーマシューティカルズ インコーポレーテッド 持続放出のための医薬調合物
DE60210402T2 (de) 2001-05-18 2006-12-07 Chiron Corp., Emeryville System zur Abgabe einer Tobramycin-Formulierung
SI1273292T1 (en) 2001-07-02 2004-12-31 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
WO2003035030A1 (en) * 2001-10-24 2003-05-01 Pari Gmbh Kit for the preparation of a pharmaceutical composition
TW200403072A (en) * 2002-01-23 2004-03-01 Upjohn Co Combination therapy for the treatment of bacterial infections
US7452524B2 (en) 2004-01-27 2008-11-18 Gilead Sciences, Inc. Method for improvement of tolerance for therapeutically effective agents delivered by inhalation
PL2316419T3 (pl) 2004-05-17 2012-12-31 Gilead Sciences Inc Aerolizowana kombinacja fosfomycyna/tobramycyna do leczenia bakteryjnych infekcji dróg oddechowych
US7838532B2 (en) 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
PL1962805T3 (pl) 2005-12-08 2017-01-31 Insmed Incorporated Kompozycje środków przeciwzapalnych oparte na lipidach do leczenia infekcji płucnych
US20100063005A1 (en) 2006-12-11 2010-03-11 Kaare Fiala Methods for Treating Cystic Fibrosis or Pneumonia with Bacterial Infection via Pulmonary Administration of Fosfomycin
WO2008106584A1 (en) 2007-02-28 2008-09-04 Paringenix, Inc. O-desulfated heparins treating acute exacerbations of chronic obstructive pulmonary disease
CA2742042A1 (en) 2008-10-23 2010-04-29 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
BRPI0919930A2 (pt) 2008-10-23 2016-02-16 Vertex Pharma moduladores de regulador de condutância transmembrana de fibrose cística
JP2013512193A (ja) 2009-11-24 2013-04-11 ギリアード サイエンシーズ， インコーポレイテッド 慢性閉塞性肺疾患の処置のための吸入型ホスホマイシン／トブラマイシン

Also Published As

Publication number Publication date
SI2316419T1 (sl) 2012-10-30
PL2316419T3 (pl) 2012-12-31
HK1151191A1 (en) 2012-01-27
US20110189103A1 (en) 2011-08-04
PL1750667T3 (pl) 2011-06-30
EP2316419A1 (en) 2011-05-04
JP4745340B2 (ja) 2011-08-10
PT2316419E (pt) 2012-10-22
IL179277A (en) 2013-04-30
ATE493969T1 (de) 2011-01-15
WO2005110022A3 (en) 2006-04-06
US20070218013A1 (en) 2007-09-20
EP1750667A2 (en) 2007-02-14
DE602005025754D1 (de) 2011-02-17
EP1750667B1 (en) 2011-01-05
BRPI0509026A (pt) 2007-09-18
SI1750667T1 (sl) 2011-04-29
AU2009243536A1 (en) 2009-12-24
US20130071442A1 (en) 2013-03-21
DK1750667T3 (da) 2011-04-26
TW200608983A (en) 2006-03-16
CY1113283T1 (el) 2016-04-13
ES2392389T3 (es) 2012-12-10
US7943118B2 (en) 2011-05-17
ES2388420T3 (es) 2012-10-15
CY1112004T1 (el) 2015-11-04
AU2005244153B2 (en) 2009-10-29
DK2316419T3 (da) 2012-10-22
EP2266534A1 (en) 2010-12-29
PT1750667E (pt) 2011-03-11
CA2564546C (en) 2013-02-26
EP2266534B1 (en) 2012-09-26
ES2358024T3 (es) 2011-05-04
EP1750667A4 (en) 2007-07-11
JP2007538075A (ja) 2007-12-27
IL225529A (en) 2014-08-31
IL179277A0 (en) 2007-05-15
US8980226B2 (en) 2015-03-17
AU2005244153A1 (en) 2005-11-24
CA2564546A1 (en) 2005-11-24
DK2266534T3 (da) 2013-01-14
US8361444B2 (en) 2013-01-29
TWI409074B (zh) 2013-09-21
IL225529A0 (en) 2013-06-27
EP2316419B1 (en) 2012-07-11
SI2266534T1 (sl) 2012-12-31
HK1157637A1 (en) 2012-07-06
PT2266534E (pt) 2012-10-09
US8409549B2 (en) 2013-04-02
PL2266534T3 (pl) 2013-02-28
US20110117030A1 (en) 2011-05-19
WO2005110022A2 (en) 2005-11-24
AR048793A1 (es) 2006-05-24
AU2009243536B2 (en) 2012-03-22

Similar Documents

Publication Publication Date Title
CY1113319T1 (el) Συνδυασμος αερολυματοποιημενης φως φομυκινης/τομπραμυκινης για την αγωγη τησκυστικης ινωσης
BRPI0414220A (pt) composição antimicrobiana, métodos de prevenir e/ou tratar uma aflição, um paciente quanto a um resfriado comum e/ou angústia respiratória causados por uma infecção microbiana, uma infecção em tecido mamìfero de um paciente, de descolonizar pelo menos uma porção das cavidades nasais, narinas anteriores e/ou nasofaringe, pelo menos uma porção da garganta/esÈfago e pelo menos uma porção da cavidade oral de um paciente de microorganismos, de matar ou inativar microorganismo, de fornecer eficácia antomicrobiana residual em uma superfìcie e em um tedido mamìfero de um paciente, de tratar uma infecção do ouvido médio, a sinusite crÈnica e impetigo na pele e uma queimadura, de fabricar uma composição antimicrobiana, e de liberar um componente antimicrobiano a uma superficìe, e, sistema de liberação para um componente antimicrobiano
ECSP077182A (es) Metodos para el tratamiento de infecciones endobronquiales
EP1838303A4 (en) USE OF DIINDOLYLMETHAN-RELATED INDOLAS FOR THE TREATMENT AND PREVENTION OF DISEASES RELATED TO THE RESPIRATORY SYNCYTIAL VIRUS
ECSP066608A (es) Suspensiones acuosas de ciclesonide para nebulización
DE502005005498D1 (de) Verfahren zur Herstellung fester Treibmittelpräparationen
NO20076086L (no) Formuleringer for endring av de biofysiske egenskapene til slimhinnene
UY26269A1 (es) Formulación de sal común y moxifloxacina
HN1999000183A (es) Preparado farmaceuticos de moxifloxacina
NO20054767L (no) Sammensetninger omfattende apomorfin for inhalering i lunge
BR0112330A (pt) Formulações de macrolìdeos para inalação e seus usos para o tratamento de infecções endobrÈnquicas
SI2158901T1 (en) ALFA AZTREONAM LIZINAT
AU2003225131A1 (en) 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo' b! thiophene-2-carboxylic acid derivatives as interieukin-4 gene expression inhibitors
EP1305042A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF SLEW-TONE INFECTIONS
US20210352905A1 (en) Compositions and methods to disinfect, treat and prevent microbial infections
TR200101841T2 (tr) Enfeksiyonlardan korunmak ve enfeksiyon tedavisi için bifosfonatların kullanılmaları
BR0210522A (pt) Processo para tratamento de carcaça de animal
BRPI0211025B8 (pt) um novo composto para o tratamento da impotência
TR200101433T2 (tr) Enfeksiyonların tedavisinde fosfonoformik asit türevlerinin kullanımı.
MXPA05010629A (es) Vehiculo enmascarador del sabor para particulas de oxazolidinona recubiertas.
ATE333288T1 (de) Gezielte freisetzung von arzneimitteln zur behandlung von virusinfektionen
JP2023533028A (ja) 微生物感染を消毒、処置および予防するための組成物および方法
GB2405338A (en) Method of prophylaxis of infection
EP1408941A4 (en) PHARMACEUTICAL COMPOSITION AND ITS MANUFACTURING PROCESS
CN105477667A (zh) 一种鹅舍的消毒方法